Business Wire·Mar 19, 2026, 4:05 PM ET

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

ZURA

Zura Bio Limited reported financial results for the full year ended December 31, 2025, and provided corporate updates.
Topline data from the Phase 2 TibuSHIELD study evaluating tibulizumab in hidradenitis suppurativa is expected in the fourth quarter of 2026.
Topline data from the Phase 2 TibuSURE study evaluating tibulizumab in systemic sclerosis is anticipated in the first half of 2027.
The Phase 2 TibuSHIELD study enrollment was expanded to 225 participants to enhance statistical power.
Zura completed an underwritten public offering in February 2026, generating approximately $144 million in gross proceeds.
Cash and cash equivalents were $109.4 million as of December 31, 2025.
Post-financing cash resources are expected to support planned operations through at least the end of 2028.
Sandeep Kulkarni, M.D., was appointed Chief Executive Officer in January 2026.
Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., joined the Board of Directors in February 2026.
Research and development expenses were $42.1 million for 2025, an increase from $24.4 million in 2024.
General and administrative expenses were $33.2 million for 2025, compared to $30.8 million in 2024.
The net loss for the year ended December 31, 2025, was $68.7 million.
Net loss attributable to Class A ordinary shareholders was $99.4 million, or $(1.06) per share, for 2025.
Zura continues to evaluate development strategies for crebankitug (ZB‑168) and torudokimab (ZB‑880) based on clinical data and the competitive landscape.